FDA Approval of Theobromie - Search News

FDA, Alnylam

Alnylam drug wins FDA approval for progressive heart disease

Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce cardiovascular-related death and hospitalizations. This indication was widely expected among investors and is similar to the indications given for competing therapies.

ConsumerAffairs · 16h

FDA greenlights new drug to treat a serious type of heart disease

Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals’ treatment for a progr

MarketWatch · 1d

Alnylam's Amvuttra Gets Approval for Expanded Indication From FDA

Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.

FDA approves vutrisiran for ATTR amyloidosis with cardiomyopathy

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...

MedPage Today on MSN1d

Vutrisiran Snags FDA Approval for TTR Amyloidosis Cardiomyopathy

Gene-silencing therapy vutrisiran (Amvuttra) graduated to a broad indication in treatment of transthyretin amyloidosis ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results